Vaxart says BARDA-backed COVID-19 oral vaccine trial funding updated to about $345 million

Vaxart, Inc

Vaxart, Inc

VXRT

0.00
  • Vaxart entered a BARDA contract modification via Advanced Technology International for its Phase 2b COVID-19 oral pill vaccine trial.
  • Total estimated funding available is about USD 345 million, down about USD 116 million following a BARDA-ordered partial termination on Aug. 5, 2025.
  • Modification releases about USD 29 million to complete the trial, expand exploratory safety and efficacy analyses.
  • Plans 12-month data from the 400-participant sentinel cohort in coming weeks.
  • Targets 12-month results from the 5,085-participant main cohort in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.